Science Translational Medicine, Journal Year: 2024, Volume and Issue: 16(770)
Published: Oct. 23, 2024
Current COVID-19 vaccines induce suboptimal respiratory mucosal immunity even after mRNA boosters (Declercq et al . and Lasrado ., this issue).
Language: Английский
Emerging Microbes & Infections, Journal Year: 2025, Volume and Issue: unknown
Published: March 12, 2025
Mucosal immunity is crucial for preventing the infection and transmission of respiratory viruses. Nasal antibody inversely correlated with a lower risk However, current reference standard nasal assessment serum-based, mainly consisting monomeric IgG IgA. The applicability serum-derived standards assessing antibodies, mostly dimeric or polymeric secretory IgA (sIgA), remains unvalidated. Herein, we first proved that sera-derived was not applicable antibodies. Using non-homologous as calibrator introduces systematic error up to 10 times, which does benefit understanding mucosal response. Therefore, attempted develop two candidate (CS1, CS2) using lining fluids (NMLFs) collected from SARS-CoV-2 Omicron convalescents intranasal vaccine recipients, CS3 sIgA monoclonal antibody. CS2 exhibited broad-spectrum binding activity against 12 strains, including all tested subvariants. A collaborative study conducted by seven laboratories demonstrated improved harmonization inter-laboratory variability (pre-standardization geometric coefficients variance, 14-314%; post-standardization, 3-35%). ensures an accurate Thus, established national evaluating SARS-CoV-2-specific antibodies (Lot: 300052-202401, 1000 U/mL). Our work provides benchmark vaccines inspires new avenues developing other vaccines.
Language: Английский
Citations
0
International Immunopharmacology, Journal Year: 2025, Volume and Issue: 153, P. 114512 - 114512
Published: March 24, 2025
Language: Английский
Citations
0
Seminars in Respiratory and Critical Care Medicine, Journal Year: 2025, Volume and Issue: unknown
Published: March 31, 2025
Abstract Whenever a new COVID-19 vaccination season starts, we must face challenges, including which vaccines to use, the update of high-risk groups be vaccinated, and especially type amount information communicated people in order promote vaccination. recommendations should fit these specific conditions. The use effective against predominant SARS-CoV-2 virus variants extent immune response (waning immunity) are key aspects try protect better populations. Updated currently swiftly available. However, number vaccinated with any additional booster dose is declining. Improved health training for care professionals, together tools make simpler recommendations, can encourage higher rates. Addressing challenges essential improve coverage ensure adequate protection evolving threats. has become constant presence our society. changes but neither endemic nor seasonal so far. Omicron variant prevailed nearly 2 years now several its subvariants like JN.1, KP.2, or XEC dominant ones. In this moving situation, main message same: safe effective. role current efforts mitigate severity disease reduce risk complications death, instead preventing most infections. New at different stages clinical research.
Language: Английский
Citations
0
Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)
Published: April 1, 2025
Language: Английский
Citations
0
Science Translational Medicine, Journal Year: 2024, Volume and Issue: 16(770)
Published: Oct. 23, 2024
Current COVID-19 vaccines induce suboptimal respiratory mucosal immunity even after mRNA boosters (Declercq et al . and Lasrado ., this issue).
Language: Английский
Citations
2